Dr Thierry André talks to ecancertv at the ESMO 14^th World Congress on Gastrointestinal Cancer (WCGC) in Barcelona.

As a medical oncologist with an interest in gastrointestinal cancer, Dr André gives his perspective on some of the important topics being discussed at the meeting. Specifically he mentions the use of new drugs for the management of patients with metastatic colorectal cancer (mCRC).

Dr André also talks about the TML study that looked at the continuation of bevacizumab in the second line setting, commenting on results from new subgroup analyses presented at the WCGC.

This programme was supported by BAYER.